Novo Nordisk has submitted a marketing application for Cagrisema to the US Food and Drug Administration, the first weekly GLP-1 and insulin analogue combination therapy for weight management.

Zhitongcaijing · 1d ago
Novo Nordisk has submitted a marketing application for Cagrisema to the US Food and Drug Administration, the first weekly GLP-1 and insulin analogue combination therapy for weight management.